{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:42:02Z","timestamp":1790613722352,"version":"4.1.0"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,11,21]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.2967\/jnumed.125.270814","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:15:55Z","timestamp":1767111355000},"page":"360-365","source":"Crossref","is-referenced-by-count":2,"title":["BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of\n                    <sup>225<\/sup>\n                    Ac-GPC3 (BAY 3547926) in Patients with Advanced Hepatocellular Carcinoma"],"prefix":"10.2967","volume":"67","author":[{"given":"Jorrit","family":"Tjeertes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Dostalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Glaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Pelekanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Pinkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Ratih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamal","family":"Subramanyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wilson Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Junger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2026030205300687000_67.3.360.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2026030205300687000_67.3.360.2","unstructured":"GLOBOCAN 2022. Cancer today: liver. International Agency for Research on Cancer website. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/11-liver-and-intrahepatic-bile-ducts-fact-sheet.pdf. Accessed February 2025."},{"key":"2026030205300687000_67.3.360.3","unstructured":"GLOBOCAN 2022. Cancer tomorrow: liver and intrahepatic bile ducts. International Agency for Research on Cancer website. https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/isotype?cancers=11&single_unit=50000&types=0. Accessed February 2025."},{"key":"2026030205300687000_67.3.360.4","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2024.03.13"},{"key":"2026030205300687000_67.3.360.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"2026030205300687000_67.3.360.6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"2026030205300687000_67.3.360.7","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466"},{"key":"2026030205300687000_67.3.360.8","doi-asserted-by":"crossref","unstructured":"Jemal A Ward EM Johnson CJ . Annual report to the nation on the status of cancer, 1975\u20132014, featuring survival. J Natl Cancer Inst. 2017;109","DOI":"10.1093\/jnci\/djx030"},{"key":"2026030205300687000_67.3.360.9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol."},{"key":"2026030205300687000_67.3.360.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.003"},{"key":"2026030205300687000_67.3.360.11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824208"},{"key":"2026030205300687000_67.3.360.12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHC.S116513","article-title":"GPC-3 in hepatocellular carcinoma: current perspectives","volume":"3","author":"Wu","year":"2016","journal-title":"J Hepatocell Carcinoma."},{"key":"2026030205300687000_67.3.360.13","doi-asserted-by":"publisher","DOI":"10.1043\/1543-2165-132.11.1723"},{"key":"2026030205300687000_67.3.360.14","doi-asserted-by":"publisher","DOI":"10.1309\/HCQWPWD50XHD2DW6"},{"key":"2026030205300687000_67.3.360.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2"},{"key":"2026030205300687000_67.3.360.16","doi-asserted-by":"crossref","first-page":"viii234","DOI":"10.1093\/annonc\/mdy282.080","article-title":"A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma","volume":"29","author":"Cheng","year":"2018","journal-title":"Ann Oncol."},{"key":"2026030205300687000_67.3.360.17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016","journal-title":"J Hepatol."},{"key":"2026030205300687000_67.3.360.18","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1038\/s41467-022-32952-3","article-title":"Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours","volume":"13","author":"Sano","year":"2022","journal-title":"Nat Commun."},{"key":"2026030205300687000_67.3.360.19","first-page":"156","article-title":"Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy","volume":"13","author":"Li","year":"2021","journal-title":"Am J Transl Res."},{"key":"2026030205300687000_67.3.360.20","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: a review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA Oncol."},{"key":"2026030205300687000_67.3.360.21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14712598.2016.1185412","article-title":"Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle","volume":"16","author":"Dekempeneer","year":"2016","journal-title":"Expert Opin Biol Ther."},{"key":"2026030205300687000_67.3.360.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2026030205300687000_67.3.360.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263230"},{"key":"2026030205300687000_67.3.360.24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026030205300687000_67.3.360.25","unstructured":"Regulation (EU) 2017\/746 of the European Parliament and of the Council of 5 April 2017 on in\u00a0vitro diagnostic medical devices and repealing Directive 98\/79\/EC and Commission Decision 2010\/227\/EU. EUR-Lex website. https:\/\/eur-lex.europa.eu\/eli\/reg\/2017\/746\/oj\/eng. Accessed March 2025."},{"key":"2026030205300687000_67.3.360.26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/19466315.2024.2333388","article-title":"Joint TITE-CRM: a design for dose finding studies for therapies with late-onset safety and activity outcomes","volume":"17","author":"Barnett","year":"2025","journal-title":"Stat Biopharm Res."},{"key":"2026030205300687000_67.3.360.27","doi-asserted-by":"crossref","first-page":"S634","DOI":"10.1016\/j.annonc.2023.09.2185","article-title":"Phase I\/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: preliminary dose escalation results","volume":"34","author":"Yong Hong","year":"2023","journal-title":"Ann Oncol."},{"key":"2026030205300687000_67.3.360.28","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT111"},{"key":"2026030205300687000_67.3.360.29","unstructured":"NAYA biosciences announces initiation of phase 1\/2a clinical trial for its GPC3-targeted NK engager bispecific antibody in patients with hepatocellular carcinoma. GlobeNewswire website. https:\/\/www.globenewswire.com\/news-release\/2024\/10\/24\/2968749\/0\/en\/NAYA-Biosciences-Announces-Initiation-of-Phase-1-2a-Clinical-Trial-for-its-GPC3-targeted-NK-Engager-Bispecific-Antibody-in-Patients-with-Hepatocellular-Carcinoma.html. Accessed March 2025."},{"key":"2026030205300687000_67.3.360.30","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2024.42.16_suppl.3091","article-title":"Phase Ib portion of the ACTION-1 phase Ib\/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: safety and efficacy findings [abstract]","volume":"42","author":"Halperin","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026030205300687000_67.3.360.31","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-23-3746","article-title":"Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-Macropa-Pelgifatamab): a targeted alpha therapy for prostate cancer","volume":"30","author":"Schatz","year":"2024","journal-title":"Clin Cancer Res."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:30:28Z","timestamp":1772458228000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.2967\/jnumed.125.270814"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270814","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}